Article
Public, Environmental & Occupational Health
Manida Suksawat, Jutarop Phetcharaburanin, Poramate Klanrit, Nisana Namwat, Narong Khuntikeo, Attapon Titapun, Apiwat Jarearnrat, Vanlakhone Vilayhong, Prakasit Sa-ngiamwibool, Anchalee Techasen, Arporn Wangwiwatsin, Panupong Mahalapbutr, Jia V. Li, Watcharin Loilome
Summary: This study used metabolomics to analyze the metabolic characteristics in tissues and sera of CCA patients, and identified predictive biomarkers for gemcitabine and cisplatin sensitivity. These biomarkers can not only predict chemotherapy response, but also minimize the adverse effects of chemotherapy.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
Kun Gao, Shuhua Chen, Xiangyu Yang
Summary: The upregulation of HOTTIP in cholangiocarcinoma patients is associated with therapeutic responsiveness and prognosis. Silencing HOTTIP increases chemotherapy sensitivity by weakening proliferation and colony formation and increasing apoptosis. HOTTIP modulates sensitivity to cisplatin and gemcitabine in cholangiocarcinoma through the HOTTIP/miR-637/LASP1 regulatory axis, providing new opportunities for treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Maen Abdelrahim, Abdullah Esmail, Jiaqiong Xu, Godsfavour Umoru, Hadeel Al-Rawi, Ashish Saharia, Ala Abudayyeh, David Victor, Robert McMillan, Sudha Kodali, Rafik M. Ghobrial
Summary: This study investigates the potential efficacy of Gemcitabine plus Cisplatin as a neo-adjuvant treatment for cholangiocarcinoma patients prior to liver transplantation. The results suggest improved overall survival outcomes with Gemcitabine plus Cisplatin compared to non-Gemcitabine/Cisplatin regimens in these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hyehyun Jeong, Kyu-pyo Kim, Jae Ho Jeong, Dae Wook Hwang, Jae Hoon Lee, Ki-Hun Kim, Deok-Bog Moon, Myung Ah Lee, Se Jun Park, Hong Jae Chon, Jin-hong Park, Ji Sung Lee, Baek-Yeol Ryoo, Changhoon Yoo
Summary: The effectiveness of adjuvant gemcitabine plus cisplatin (GemCis) therapy was evaluated in a homogeneous group of high-risk patients with resected, lymph node-positive extrahepatic cholangiocarcinoma. The study found that adjuvant GemCis did not improve survival outcomes compared with capecitabine in this patient population.
Article
Gastroenterology & Hepatology
Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Daisuke Sakai, Hidetoshi Eguchi, Hideo Baba, Satoru Seo, Akinobu Taketomi, Tadatoshi Takayama, Hiroki Yamaue, Masahiro Takahashi, Masayuki Sho, Keiko Kamei, Jiro Fujimoto, Masanori Toyoda, Junzo Shimizu, Takuma Goto, Yoshitaro Shindo, Kenichi Yoshimura, Etsuro Hatano, Hiroaki Nagano
Summary: This study demonstrates that adding S-1 to GC can improve overall survival and response rate in patients with advanced biliary tract cancer, making GCS a potential new first-line standard chemotherapy. Additionally, GCS is being tested in a neoadjuvant trial to further evaluate its efficacy.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Margherita Rimini, Lorenzo Fornaro, Sara Lonardi, Monica Niger, Daniele Lavacchi, Tiziana Pressiani, Jessica Lucchetti, Guido Giordano, Andrea Pretta, Emiliano Tamburini, Chiara Pirrone, Ilario Giovanni Rapposelli, Anna Diana, Erika Martinelli, Ingrid Garajova, Francesca Simionato, Marta Schirripa, Vincenzo Formica, Caterina Vivaldi, Enrico Caliman, Mario Domenico Rizzato, Valentina Zanuso, Federico Nichetti, Lorenzo Angotti, Matteo Landriscina, Mario Scartozzi, Matteo Ramundo, Alessandro Pastorino, Bruno Daniele, Noemi Cornara, Mara Persano, Eleonora Gusmaroli, Riccardo Cerantola, Francesca Salani, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu, Lorenza Rimassa, Lorenzo Antonuzzo, Andrea Casadei-Gardini
Summary: This study investigated the efficacy and safety of the combination of durvalumab, gemcitabine, and cisplatin in patients with advanced biliary tract cancer. The results showed that the median progression-free survival was 8.9 months, and the median overall survival was 12.9 months. The overall response rate was 34.5% and the disease control rate was 87.6%. Adverse events were mainly mild, with a small percentage of immune-mediated adverse events observed.
LIVER INTERNATIONAL
(2023)
Article
Medicine, General & Internal
Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo
Summary: The study aimed to investigate the predictive and prognostic values of several biomarkers in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin. The results showed that increased intratumoral expression of RRM1 may predict poor survival in patients with this chemotherapy regimen.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Tian-mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-jie Tao, Xi-yun Chen, Qin Han, Zhuo Cheng, Pei-pei Shang, Yu-long Dong, He-ming Xu, Lie-ping Guo, Dong-sheng Chen, Yun-jie Song, Chuang Qi, Wang-long Deng, Zhen-gang Yuan
Summary: This study is a phase II clinical trial investigating the efficacy of the anti-PD-1 antibody sintilimab in combination with chemotherapy as first-line treatment for patients with advanced biliary tract cancers. The primary endpoint was overall survival, and secondary endpoints included toxicities, progression-free survival, and objective response rate.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Hiroto Inoue, Akiko Todaka, Kentaro Yamazaki, Kunihiro Fushiki, Hiromichi Shirasu, Takeshi Kawakami, Takahiro Tsushima, Satoshi Hamauchi, Tomoya Yokota, Nozomu Machida, Akira Fukutomi, Yusuke Onozawa, Akira Andoh, Hirofumi Yasui
Summary: This retrospective study analyzed the efficacy and safety of S-1 as a second-line therapy following GC in 116 patients with unresectable or recurrent BTC. The results indicated that the efficacy and safety of S-1 following GC were comparable to S-1 following GEM monotherapy.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Oncology
Stijn Franssen, Jessica J. Holster, Joshua S. Jolissaint, Lynn E. Nooijen, Andrea Cercek, Michael I. D'Angelica, Marjolein Y. V. Homs, Alice C. Wei, Vinod P. Balachandran, Jeffrey A. Drebin, James J. Harding, Nancy E. Kemeny, T. Peter Kingham, Heinz-Josef Kluempen, Bianca Mostert, Rutger-Jan Swijnenburg, Kevin C. Soares, William R. Jarnagin, Bas Groot Koerkamp
Summary: This study compared the efficacy of systemic gemcitabine and cisplatin (gem-cis) versus hepatic arterial infusion pump (HAIP) chemotherapy in patients with liver-confined unresectable intrahepatic cholangiocarcinoma (iCCA). The results showed that patients treated with HAIP chemotherapy had significantly higher overall survival rates compared to those treated with gem-cis.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Christian Mueller, Jazan Omari, Konrad Mohnike, Caroline Baer, Maciej Pech, Verena Keitel, Marino Venerito
Summary: Personalized treatment based on multidisciplinary discussion is crucial for improving survival and ensuring safety in patients with progressing unresectable biliary tract cancer.
Article
Oncology
Arathi Mohan, Kent A. Grif, Fulei Wuchu, David B. Zhen, Chandan Kumar-Sinha, Oxana Crysler, David Hsiehchen, Thomas Enzler, Dominique Dippman, Valerie Gunchick, Abhinav Achreja, Olamide Animasahun, Srinadh Choppara, Minal Nenwani, Arul M. Chinnaiyan, Deepak Nagrath, Mark M. Zalupski, Vaibhav Sahai
Summary: This study investigated the effect of the novel inhibitor, Devimistat, in patients with advanced biliary tract cancer. The results showed that Devimistat in combination with Gemcitabine and Cisplatin had a synergistic effect on cells and significantly decreased oxygen consumption rate. In the clinical trial, the combination therapy of Devimistat with Gemcitabine and Cisplatin demonstrated good safety and efficacy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Robert C. G. Martin, Kerri A. Simo, Paul Hansen, Flavio Rocha, Prejesh Philips, Kelly M. McMasters, Clifton M. Tatum, Lawrence R. Kelly, Michael Driscoll, Vivek R. Sharma, Todd S. Crocenzi, Charles R. Scoggins
Summary: This study assessed the efficacy of irinotecan drug-eluting beads (DEBIRI) therapy in combination with systemic therapy for unresectable intrahepatic cholangiocarcinoma (ICC). The results showed that the combination therapy significantly improved downsizing to resection, progression-free survival, and overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Elaine S. Tan, Biwei Cao, Jongphil Kim, Taymeyah E. Al-Toubah, Rutika Mehta, Barbara A. Centeno, Richard D. Kim
Summary: The addition of copanlisib to gemcitabine and cisplatin did not improve progression-free survival at 6 months in patients with advanced biliary tract cancer. Future studies could potentially use PTEN as a biomarker.
Article
Gastroenterology & Hepatology
Mitesh J. Borad, Li-Yuan Bai, Donald Richards, Kabir Mody, Joleen Hubbard, Sun Young Rha, John Soong, Daniel McCormick, Emmett Tse, Daniel O'Brien, Ahmad Bayat, Daniel Ahn, S. Lindsey Davis, Joon Oh Park, Do-Youn Oh
Summary: This study investigates the safety and efficacy of silmitasertib in combination with gemcitabine and cisplatin for the treatment of cholangiocarcinoma. The results show promising preliminary evidence of efficacy for the first-line treatment of locally advanced/metastatic cholangiocarcinoma.
Article
Oncology
Kenneth L. Pitter, Dana L. Casey, Yue C. Lu, Margaret Hannum, Zhigang Zhang, Xinmao Song, Isabella Pecorari, Biko McMillan, Jennifer Ma, Robert M. Samstein, Isaac X. Pei, Atif J. Khan, Lior Z. Braunstein, Luc G. T. Morris, Christopher A. Barker, Andreas Rimner, Kaled M. Alektiar, Paul B. Romesser, Christopher H. Crane, Joachim Yahalom, Michael J. Zelefsky, Howard Scher, Jonine L. Bernstein, Diana L. Mandelker, Britta Weigelt, Jorge S. Reis-Filho, Nancy Y. Lee, Simon N. Powell, Timothy A. Chan, Nadeem Riaz, Jeremy Setton
Summary: The study demonstrates that somatic ATM inactivation is associated with significantly improved tumor control following radiation therapy, especially in tumors with biallelic ATM inactivation. Interestingly, ATM LoF is highly predictive of outcome in TP53 wild-type tumors but not among TP53-mutant tumors, offering potential clinical opportunities for genomically guided radiation therapy across multiple cancer types.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Cell Biology
Jinru Shia
Summary: Microsatellite instability (MSI) is recognized as a diverse molecular phenotype in human neoplasms, with variations in genotype and phenotype within and across tumor types. Advances in understanding this diversity have been made, but its potential impact on the effective use of current MSI detection tools is significant.
Article
Oncology
Martin R. Weiser, Meier Hsu, Philip S. Bauer, William C. Chapman, Ivan A. Gonzalez, Deyali Chatterjee, Deepak Lingam, Matthew G. Mutch, Ajaratu Keshinro, Jinru Shia, Efsevia Vakiani, Tsuyoshi Konishi, Yoshifumi Shimada, Zsofia Stadler, Neil H. Segal, Andrea Cercek, Leonard Saltz, Rona Yaeger, Anna Varghese, Maria Widmar, Iris H. Wei, Emmanouil P. Pappou, J. Joshua Smith, Garrett Nash, Philip Paty, Julio Garcia-Aguilar, Mithat Gonen
Summary: Clinical calculators and nomograms are recommended by the AJCC for providing individualized and accurate estimates of patient outcome. A third-generation clinical calculator was developed to predict cancer recurrence following resection of stage I-III colon cancer, demonstrating improved discrimination and predictive accuracy by incorporating new variables such as microsatellite genomic phenotype and tumor-infiltrating lymphocytes.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Letter
Pathology
Jaclyn F. Hechtman, Robert Soslow, Jinru Shia
Article
Pathology
Monika Vyas, Erika Hissong, Raul S. Gonzalez, Jinru Shia, Jose Jessurun
Summary: This study aimed to investigate the most common tumors that metastasize to the stomach and the morphologic features that can provide clues for investigation of metastasis and predicting the primary sites. The results showed that gastric neoplasms with a diffuse/solid growth pattern should be considered for differential diagnosis of metastatic neoplasms. Glandular neoplasms are difficult to differentiate from gastric primaries except for Mullerian neoplasms, which frequently show a papillary/micropapillary architecture.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2022)
Letter
Dermatology
Rachel E. Reingold, Brooke E. Corbett, Nina R. Blank, Rachel A. Day, Michael J. McManus, Jennifer Ma, Stephen W. Dusza, Mario E. Lacouture, Christopher A. Barker, Alina Markova
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Oncology
Lik Hang Lee, Lindy Davis, Lourdes Ylagan, Angela R. Omilian, Kristopher Attwood, Canan Firat, Jinru Shia, Philip B. Paty, William G. Cance
Summary: High expression of focal adhesion kinase (FAK) in colorectal cancer is associated with increased recurrence rate and reduced survival in stage I patients. FAK may serve as an important biomarker for predicting recurrence in stage I colorectal cancer, suggesting the need for more rigorous surveillance protocols for these patients.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Jin K. Kim, Chin-Tung Chen, Ajaratu Keshinro, Asama Khan, Canan Firat, Chad Vanderbilt, Neil Segal, Zsofia Stadler, Jinru Shia, Vinod P. Balachandran, Martin R. Weiser
Summary: T cells in colon tumors with deficient DNA mismatch repair (dMMR) are more clonal and have a less diverse repertoire compared to tumors with proficient mismatch repair (pMMR). This suggests that T cells clonally expand in response to MMR deficiency-induced tumor neoantigens in dMMR tumors.
Review
Pathology
Chiyun Wang, Liying Zhang, Efsevia Vakiani, Jinru Shia
Summary: The value of detecting tumor DNA mismatch repair function is widely recognized in managing patients with solid tumors. However, the current immunohistochemistry and microsatellite instability tests have limitations. Some non-colorectal cases may lose mismatch repair function in immunohistochemistry but do not meet the current criteria for high microsatellite instability. These cases may require further genetic testing for Lynch syndrome detection.
Article
Hematology
Doris M. Ponce, Amin M. Alousi, Ryotaro Nakamura, John Slingerland, Marco Calafiore, Karamjeet S. Sandhu, Juliet N. Barker, Sean Devlin, Jinru Shia, Sergio Giralt, Miguel-Angel Perales, Gillian Moore, Samira Fatmi, Cristina Soto, Antonio Gomes, Paul Giardina, LeeAnn Marcello, Xiaoqiang Yan, Tom Tang, Kevin Dreyer, Jianmin Chen, William L. Daley, Jonathan U. Peled, Marcel R. M. van den Brink, Alan M. Hanash
Summary: This study evaluated the safety and efficacy of a novel recombinant human interleukin-22 dimer, F-652, in combination with systemic corticosteroids for treatment of newly diagnosed lower gastrointestinal acute GVHD. The results showed that 70% of patients achieved a satisfactory treatment response, demonstrating the potential effect of this combination therapy for improving GVHD-associated dysbiosis.
Article
Multidisciplinary Sciences
Luis A. Rojas, Zachary Sethna, Kevin C. Soares, Cristina Olcese, Nan Pang, Erin Patterson, Jayon Lihm, Nicholas Ceglia, Pablo Guasp, Alexander Chu, Rebecca Yu, Adrienne Kaya Chandra, Theresa Waters, Jennifer Ruan, Masataka Amisaki, Abderezak Zebboudj, Zagaa Odgerel, George Payne, Evelyna Derhovanessian, Felicitas Mueller, Ina Rhee, Mahesh Yadav, Anton Dobrin, Michel Sadelain, Marta Luksza, Noah Cohen, Laura Tang, Olca Basturk, Mithat Goenen, Seth Katz, Richard Kinh Do, Andrew S. Epstein, Parisa Momtaz, Wungki Park, Ryan Sugarman, Anna M. Varghese, Elizabeth Won, Avni Desai, Alice C. Wei, Michael I. D'Angelica, T. Peter Kingham, Ira Mellman, Taha Merghoub, Jedd D. Wolchok, Ugur Sahin, Oezlem Tuereci, Benjamin D. Greenbaum, William R. Jarnagin, Jeffrey Drebin, Eileen M. O'Reilly, Vinod P. Balachandran
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a high mortality rate, but it can be targeted using mutation-derived T cell neoantigens as vaccines. In this phase I trial, researchers synthesized individualized mRNA neoantigen vaccines from PDAC tumors and administered them to patients along with atezolizumab, autogene cevumeran, and mFOLFIRINOX chemotherapy. The results showed that the autogene cevumeran vaccine induced neoantigen-specific T cells in patients, and those with vaccine-expanded T cells had a longer recurrence-free survival.
Article
Oncology
Naryan Rustgi, Ann Maria, Nicolas Toumbacaris, Huiyong Zhao, Katherine Kargus, Morgan Bryant, Alexandra Waksmundzki, Ilinca Aricescu, Robert A. Lefkowitz, Bob T. Li, Joanne Chou, Marinela Capanu, Elisa de Stanchina, Sandra Misale, Jinru Shia, Rona Yaeger
Summary: This study aimed to explore the efficacy of combination therapy with RAF and MEK inhibitors for non-V600 BRAF-mutant tumors. The results showed that RAF inhibitors modestly inhibited signaling and growth in preclinical models of activated non-V600 BRAF mutations and allowed for a higher dose of MEK/ERK inhibitors. However, in a clinical trial, the combination treatment did not sufficiently inhibit the growth of these tumors.
Meeting Abstract
Oncology
Jennifer Ma, Luke del Balzo, Sari Safaa Khaleel, Jessica Flynn, Zhigang Zhang, Martin H. Voss, Benjamin Freeman, A. Ari Hakimi, Chung-Han Lee, Jordan Eichholz, Daniel W. Kelly, Jonathan T. Yang, Boris Mueller, Maria Isabel Carlo, Robert J. Motzer, Brandon S. Imber, Kathryn Beal, Nelson S. Moss, Ritesh Kotecha, Luke Roy George Pike
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Christine Orr, Chiyun Wang, Canan Firat, Louise C. Connell, Margaret R. Sheehan, Efsevia Vakiani, Zsofia K. Stadler, Jinru Shia
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Ajaratu Keshinro, Chad Vanderbilt, Jin K. Kim, Canan Firat, Chin-Tung Chen, Rona Yaeger, Karuna Ganesh, Neil H. Segal, Mithat Gonen, Jinru Shia, Zsofia Stadler, Martin R. Weiser
Summary: The study characterized the relationship between TIL, TMB, and genetic alterations in MSS, MSI, or mutant POLE/POLD1 colon cancer. Results showed significant differences in TIL and TMB levels between different phenotypes, which may help explain tumoral immunity and serve as predictors of response to immunotherapy.
JCO PRECISION ONCOLOGY
(2021)